Endocrine Abstracts

Introduction:Amiodarone is a life saving anti arrhythmic drug,but it has a complex side effect profile involving organs that include thyroid,lungs, liver and eyes. It is well known that patients on long term amiodarone therapy should be followed up in a structured manner including regular thyroid function tests,liver function tests,chest xray and eye examination.There are guidelines suggested by the Summary of Product Characteristics (SPC) for amiodarone...

Objectives: Delayed puberty is thought to be common in boys with Duchenne muscular dystrophy [DMD]. To date, studies addressing its frequency are not available. This study aims to report the frequency of delayed puberty in DMD from clinical examination.Methods: All boys with DMD aged at least 14 years in January 2022 known to the Glasgow paediatric neuromuscular service (2015-2022) were included. Thirty-seven boys were identified. All 37 boys had at leas...

Background: Glucocorticoid (GC) therapy is standard of care of management of Duchenne Muscular Dystrophy (DMD) but its use is associated with a range of side-effects. Weight gain leading to significant obesity is common in GC-treated boys.Aim(s): To evaluate changes in growth parameters: height-SDS, weight-SDS, body mass index (BMI)-SDS following initiation of GC in DMD.Methods: Between 2013-2019, 26 boys with DMD were commenced on...

Introduction: There is a need to understand testicular development in adolescents with Duchenne Muscular Dystrophy (DMD).Objective: To evaluate testicular development and function in DMD over 12 months.Methods: All data are presented as median(range). 23 boys aged 12.4 years (10.0, 16.8) with a bone age delay of 0.9 years (−2.4, 7.1) had physical and biochemical assessment of puberty at Month 0(M0) and Month 12(M12) and divid...

Background: Glucocorticoid (GC) therapy is the standard management for Duchenne Muscular Dystrophy (DMD), but its use is associated with significant side effects, including weight gain. Limited research exists on the impact of GC initiation on body composition in DMD, particularly regarding the timing of fat mass increase.Objective: This study aimed to assess changes in growth parameters, namely height-SDS, weight-SDS, b...

Background: Peptide Receptor Radionuclide Therapy (PRRT) is effective for gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) and received FDA approval after demonstrating improved progression-free-survival (PFS) in advanced midgut NETs. We investigated a two-decade experience with PRRT, hypothesizing that PRRT confers PFS and overall-survival (OS) advantages in patients who progress after surgery.Methods: A single-institutional NET database was re...